Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1683626rdf:typepubmed:Citationlld:pubmed
pubmed-article:1683626lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:1683626lifeskim:mentionsumls-concept:C1457887lld:lifeskim
pubmed-article:1683626lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1683626lifeskim:mentionsumls-concept:C0036341lld:lifeskim
pubmed-article:1683626lifeskim:mentionsumls-concept:C0040615lld:lifeskim
pubmed-article:1683626lifeskim:mentionsumls-concept:C2825032lld:lifeskim
pubmed-article:1683626lifeskim:mentionsumls-concept:C0332325lld:lifeskim
pubmed-article:1683626lifeskim:mentionsumls-concept:C0205197lld:lifeskim
pubmed-article:1683626lifeskim:mentionsumls-concept:C0522510lld:lifeskim
pubmed-article:1683626pubmed:issue4lld:pubmed
pubmed-article:1683626pubmed:dateCreated1992-1-6lld:pubmed
pubmed-article:1683626pubmed:abstractTextWe report 2 studies evaluating the effects of a complete and progressive neuroleptic withdrawal on the symptomatology of 2 groups of 10 young chronically ill schizophrenic inpatients. In a preliminary open study, we compare the psychiatric symptomatology during a 4-week-period before the beginning of withdrawal and during a similar period following the end of withdrawal. We observe the significative improvement of the blunted affect, the deterioration of an aspecific psychiatric symptomatology (including irritability, excitement, hostility) and the non-modification of the specific schizophrenic symptomatology (in its 3 main components: positive signs, negative signs, disorganization). The second study (a double blind one) reports the effects of a complete neuroleptic withdrawal maintained during a longer period (8 weeks): 1. The improvement of the blunted affect is transiently observed during the 2 first weeks after the end of withdrawal but not after this time. 2. The deterioration of the aspecific psychiatric symptomatology by opposition to the non-significative modification of the specific schizophrenic symptomatology is a fact confirmed by this second study. Even if we can not exclude that the influence of neuroleptic withdrawal on the specific psychotic symptoms may require a longer time frame than 8 weeks to detect, this dichotomic evolution raises the problem of the specific action of neuroleptics in this particular category of patients.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:1683626pubmed:languagefrelld:pubmed
pubmed-article:1683626pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1683626pubmed:citationSubsetIMlld:pubmed
pubmed-article:1683626pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1683626pubmed:statusMEDLINElld:pubmed
pubmed-article:1683626pubmed:issn0013-7006lld:pubmed
pubmed-article:1683626pubmed:authorpubmed-author:WolfM AMAlld:pubmed
pubmed-article:1683626pubmed:authorpubmed-author:DienerJ MJMlld:pubmed
pubmed-article:1683626pubmed:authorpubmed-author:PerettiSSlld:pubmed
pubmed-article:1683626pubmed:authorpubmed-author:BaillyLLlld:pubmed
pubmed-article:1683626pubmed:authorpubmed-author:GarneauYYlld:pubmed
pubmed-article:1683626pubmed:authorpubmed-author:MartinetJ PJPlld:pubmed
pubmed-article:1683626pubmed:issnTypePrintlld:pubmed
pubmed-article:1683626pubmed:volume17lld:pubmed
pubmed-article:1683626pubmed:ownerNLMlld:pubmed
pubmed-article:1683626pubmed:authorsCompleteYlld:pubmed
pubmed-article:1683626pubmed:pagination255-61lld:pubmed
pubmed-article:1683626pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1683626pubmed:meshHeadingpubmed-meshheading:1683626-...lld:pubmed
pubmed-article:1683626pubmed:meshHeadingpubmed-meshheading:1683626-...lld:pubmed
pubmed-article:1683626pubmed:meshHeadingpubmed-meshheading:1683626-...lld:pubmed
pubmed-article:1683626pubmed:meshHeadingpubmed-meshheading:1683626-...lld:pubmed
pubmed-article:1683626pubmed:meshHeadingpubmed-meshheading:1683626-...lld:pubmed
pubmed-article:1683626pubmed:meshHeadingpubmed-meshheading:1683626-...lld:pubmed
pubmed-article:1683626pubmed:meshHeadingpubmed-meshheading:1683626-...lld:pubmed
pubmed-article:1683626pubmed:meshHeadingpubmed-meshheading:1683626-...lld:pubmed
pubmed-article:1683626pubmed:meshHeadingpubmed-meshheading:1683626-...lld:pubmed
pubmed-article:1683626pubmed:meshHeadingpubmed-meshheading:1683626-...lld:pubmed
pubmed-article:1683626pubmed:articleTitle[Complete neuroleptic withdrawal in patients with schizophrenia with intense symptoms and resistant to treatment].lld:pubmed
pubmed-article:1683626pubmed:affiliationCentre de recherche Université Laval Robert-Giffard, Beauport, (Québec), Canada.lld:pubmed
pubmed-article:1683626pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1683626pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1683626pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:1683626pubmed:publicationTypeCase Reportslld:pubmed